<?xml version="1.0" encoding="UTF-8"?>
<p>Quinoline derivatives are popular for the treatment of malaria
 <xref rid="CIT0037" ref-type="bibr">
  <sup>37</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0038" ref-type="bibr">
  <sup>38</sup>
 </xref>. Moreover, quinoline heterocyclic containing compounds demonstrate potent anticancer activities with different modes of actions, including inhibition of proteasome, tyrosine kinases, and tubulin polymerisation
 <xref rid="CIT0039" ref-type="bibr">
  <sup>39–41</sup>
 </xref>. Previous studies have reported the antiproliferative activity of CA-4, isoCA-4 or chalcone compounds containing quinoline scaffold, either as ring A bioisoster, e.g. 
 <bold>4a</bold>
 <xref rid="CIT0023" ref-type="bibr">
  <sup>23</sup>
 </xref> and 
 <bold>4b</bold>
 <xref rid="CIT0042" ref-type="bibr">
  <sup>42</sup>
 </xref> or ring B bioisoster, e.g. 
 <bold>4c</bold>
 <xref rid="CIT0043" ref-type="bibr">
  <sup>43–45</sup>
 </xref> and 
 <bold>4d</bold>
 <xref rid="CIT0046" ref-type="bibr">
  <sup>46</sup>
 </xref>. These compounds demonstrate the potential of the quinoline ring as a template for developing more promising tubulin polymerisation inhibitors and antiproliferative agents.
</p>
